A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
Phase 1
100
about 2.7 years
18+
10 sites in CO, FL, MI +5
What this study is about
Researchers are testing if KQB198 can treat advanced solid tumor cancer in adults. The trial will also learn about the safety of KQB198. Participants will take KQB198 daily, alone or in combination with another anti-cancer drug and visit the clinic regularly.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Amivantamab
- 2.Take KQB198
- 3.Take Osimertinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
amivantamab, osimertinib
oral (Oral Tablet)
Primary: Efficacy and Optimal Biologic Dose of study treatment, as measured by Objective Response Rate (ORR) (Parts 2 and 3), Number of patients who experience treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities (Part 1)
Secondary: Concentration-time curve (AUC), Duration of response (DOR), Maximum plasma concentration (Cmax), Overall response rate (ORR), Overall survival (OS), Progression-free survival (PFS), Time to maximum plasma concentration (tmax), Time to response (TTR)